SOAT1 and primary cutaneous T-cell non-Hodgkin lymphoma: Ruxolitinib has been shown to cause a dose-dependent inhibition of cell proliferation, with concurrent activation of apoptosis, a marked and rapid inhibition of STAT activation and inhibition in DNA synthesis in CTCL cells [20].